|Application ||IHC-P, IF, FC|
|Other Accession||1048, 634, 709196|
|Isotype||Mouse / IgG1, kappa|
|Other Names||Carcinoembryonic antigen-related cell adhesion molecule 5, Carcinoembryonic antigen, CEA, Meconium antigen 100, CD66e, CEACAM5, CEA|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Carcinoembryonic Antigen (CEA) / CD66 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. Receptor for E.coli Dr adhesins.|
|Cellular Location||Cell membrane; Lipid-anchor, GPI-anchor|
|Tissue Location||Found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb reacts with nonspecific cross-reacting antigen (NCA) and shows a cross-reaction with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix.Ā
Muraro R, et. al. Cancer Research, 1985, 45:5769-80. | Siler K, et. al. Biotechnology Therapeutics, 1993, 4(3-4):163-81. | Robbins PF, et. al. International Journal of Cancer, 1993, 53(6):892-7. |
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.